The Surgical and Systemic Management of Neuroendocrine Tumors of the Pancreas

Surgical Clinics of North America

Volumn 89, Issue 1, 2009, Pages 249-266

  Abood, Gerard J ^a   Go, Aileen ^a   Malhotra, Deepak ^a   Shoup, Margo ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Metastatic neuroendocrine tumor; Neuroendocrine tumor; Surgical intervention; Surgical resection

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CHLOROZOTOCIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; LANTREOTIDE; OCTREOTIDE; PEGINTERFERON ALPHA2B; PLACEBO; RAPAMYCIN; RECOMBINANT ALPHA INTERFERON; S 0158; SOMATOSTATIN DERIVATIVE; SORAFENIB; STREPTOZOCIN; SUNITINIB; TEMOZOLAMIDE; TEMSIROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; ARTIFICIAL EMBOLISM; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER SURGERY; CHOLELITHIASIS; CLINICAL TRIAL; CYTOTOXICITY; DIARRHEA; DRUG DOSE TITRATION; DRUG TARGETING; DRUG WITHDRAWAL; GASTRINOMA; GLUCAGONOMA; HEPATIC ARTERY; HISTOPATHOLOGY; HUMAN; INSULINOMA; LIVER METASTASIS; LYMPHOCYTOPENIA; MOLECULAR GENETICS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; OPPORTUNISTIC INFECTION; PANCREAS ISLET CELL TUMOR; PRIORITY JOURNAL; REPEATED DRUG DOSE; REVIEW; SOMATOSTATINOMA; STEATORRHEA; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS, ALKYLATING; CARCINOMA, NEUROENDOCRINE; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; DACARBAZINE; GASTRINOMA; HUMANS; INSULINOMA; LIVER NEOPLASMS; OCTREOTIDE; PANCREATIC NEOPLASMS; SOMATOSTATIN; VIPOMA;

EID: 58749114792     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2008.10.001     Document Type: Review

References (117)

1. Kloppel G., and Heitz P.U. Classification of normal and neoplastic neuroendocrine cells. Ann N Y Acad Sci 733 (1994) 19-23
2. Delcore R., and Friesen S.R. Gastrointestinal neuroendocrine tumors. J Am Coll Surg 178 2 (1994) 187-211
3. Rindi G., Capella C., and Solcia E. Introduction to a revised clinicopathological classification of neuroendocrine tumors of the gastroenteropancreatic tract. Q J Nucl Med 44 1 (2000) 13-21
4. Nash S.V., and Said J.W. Gastroenteropancreatic neuroendocrine tumors: a histochemical and immunohistochemical study of epithelial (keratin proteins, carcinoembryonic antigen) and neuroendocrine (neuron-specific enolase, bombesin and chromogranin) markers in foregut, midgut, and hindgut tumors. Am J Clin Pathol 86 4 (1986) 415-422
5. Metz D.C., and Jensen R.T. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 135 (2008) 1469-1492
6. Cheslyn-Curtis S., Sitaram V., and Williamson R.C. Management of non-functioning neuroendocrine tumours of the pancreas. Br J Surg 80 5 (1993) 625-627
7. Oberg K., and Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 19 5 (2005) 753-781
8. Grama D., Eriksson B., Martensson H., et al. Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes. World J Surg 16 4 (1992) 632-639
9. Chamberlain R.S., Canes D., Brown K.T., et al. Hepatic neuroendocrine metastases: does intervention alter outcomes?. J Am Coll Surg 190 4 (2000) 432-445
10. Eriguchi N., Aoyagi S., Imayama H., et al. Endocrine tumor of the pancreas: an evaluation of eighteen patients who underwent resection followed by long-term survival. Kurume Med J 46 2 (1999) 105-110
11. Madura J.A., Cummings O.W., Wiebke E.A., et al. Nonfunctioning islet cell tumors of the pancreas: a difficult diagnosis but one worth the effort. Am Surg 63 7 (1997) 573-577 [discussion: 577-8]
12. Tsiotos G.G., Farnell M.B., and Sarr M.G. Are the results of pancreatectomy for pancreatic cancer improving?. World J Surg 23 9 (1999) 913-919
13. Wick M.R., and Graeme-Cook F.M. Pancreatic neuroendocrine neoplasms: a current summary of diagnostic, prognostic, and differential diagnostic information. Am J Clin Pathol 115 Suppl (2001) S28-S45
14. Rappeport E.D., Hansen C.P., Kjaer A., et al. Multidetector computed tomography and neuroendocrine pancreaticoduodenal tumors. Acta Radiol 47 3 (2006) 248-256
15. Virgolini I., Traub-Weidinger T., and Decristoforo C. Nuclear medicine in the detection and management of pancreatic islet-cell tumours. Best Pract Res Clin Endocrinol Metab 19 2 (2005) 213-227
16. Eriksson B., Orlefors H., Oberg K., et al. Developments in PET for the detection of endocrine tumours. Best Pract Res Clin Endocrinol Metab 19 2 (2005) 311-324
17. Orlefors H., Sundin A., Garske U., et al. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 90 6 (2005) 3392-3400
18. Sundin A., Eriksson B., Bergstrom M., et al. PET in the diagnosis of neuroendocrine tumors. Ann N Y Acad Sci 1014 (2004) 246-257
19. Norton J.A. Intra-operative procedures to localize endocrine tumours of the pancreas and duodenum. Ital J Gastroenterol Hepatol 31 Suppl 2 (1999) S195-S197
20. Solorzano C.C., Lee J.E., Pisters P.W., et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 130 6 (2001) 1078-1085
21. Christein J.D., Kim A.W., Golshan M.A., et al. Central pancreatectomy for the resection of benign or low malignant potential neoplasms. World J Surg 27 5 (2003) 595-598
22. Iacono C., Bortolasi L., and Serio G. Indications and technique of central pancreatectomy: early and late results. Langenbecks Arch Surg 390 3 (2005) 266-271
23. Yamaguchi K., Yokohata K., Ohkido M., et al. Which is less invasive, distal pancreatectomy or segmental resection?. Int Surg 85 4 (2000) 297-302
24. Balzano G., Zerbi A., Veronesi P., et al. Surgical treatment of benign and borderline neoplasms of the pancreatic body. Dig Surg 20 6 (2003) 506-510
25. O'Grady H.L., and Conlon K.C. Pancreatic neuroendocrine tumours. Eur J Surg Oncol 34 3 (2008) 324-332
26. Azimuddin K., and Chamberlain R.S. The surgical management of pancreatic neuroendocrine tumors. Surg Clin North Am 81 3 (2001) 511-525
27. Eckhauser F.E., Cheung P.S., Vinik A.I., et al. Nonfunctioning malignant neuroendocrine tumors of the pancreas. Surgery 100 6 (1986) 978-988
28. Gupta S., Johnson M.M., Murthy R., et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104 8 (2005) 1590-1602
29. Madoff D.C., Gupta S., Ahrar K., et al. Update on the management of neuroendocrine hepatic metastases. J Vasc Interv Radiol 17 8 (2006) 1235-1249 [quiz 1250]
30. Burgos L., and Burgos M.E. [Pancreatic neuroendocrine tumors]. Rev Med Chil 132 5 (2004) 627-634 [Spanish]
31. Tamburrano G., Paoloni A., Pietrobono D., et al. Pancreatic endocrine tumours. Ital J Gastroenterol Hepatol 31 Suppl 2 (1999) S104-S107
32. Verner J.V., and Morrison A.B. Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. Am J Med 25 3 (1958) 374-380
33. Stacpoole P.W. The glucagonoma syndrome: clinical features, diagnosis, and treatment. Endocr Rev 2 3 (1981) 347-361
34. Ganda O.P., Weir G.C., Soeldner J.S., et al. "Somatostatinoma:" a somatostatin-containing tumor of the endocrine pancreas. N Engl J Med 296 17 (1977) 963-967
35. Perry R.R., and Vinik A.I. Endocrine tumors of the gastrointestinal tract. Annu Rev Med 47 (1996) 57-68
36. Park B.J., Alexander H.R., Libutti S.K., et al. Operative management of islet-cell tumors arising in the head of the pancreas. Surgery 124 6 (1998) 1056-1061 [discussion: 1061-2]
37. Sheppard B.C., Norton J.A., Doppman J.L., et al. Management of islet cell tumors in patients with multiple endocrine neoplasia: a prospective study. Surgery 106 6 (1989) 1108-1117 [discussion: 1117-8]
38. Machado M.C., da Cunha J.E., Jukemura J., et al. Insulinoma: diagnostic strategies and surgical treatment. A 22-year experience. Hepatogastroenterology 48 39 (2001) 854-858
39. Ardengh J.C., Rosenbaum P., Ganc A.J., et al. Role of EUS in the preoperative localization of insulinomas compared with spiral CT. Gastrointest Endosc 51 5 (2000) 552-555
40. Ardengh J.C., Valiati L.H., and Geocze S. [Identification of insulinomas by endoscopic ultrasonography]. Rev Assoc Med Bras 50 2 (2004) 167-171 [Portuguese]
41. Aoki T., Sakon M., Ohzato H., et al. Evaluation of preoperative and intraoperative arterial stimulation and venous sampling for diagnosis and surgical resection of insulinoma. Surgery 126 5 (1999) 968-973
42. Doppman J.L., Chang R., Fraker D.L., et al. Localization of insulinomas to regions of the pancreas by intra-arterial stimulation with calcium. Ann Intern Med 123 4 (1995) 269-273
43. Boukhman M.P., Karam J.H., Shaver J., et al. Insulinoma: experience from 1950 to 1995. West J Med 169 2 (1998) 98-104
44. Hashimoto L.A., and Walsh R.M. Preoperative localization of insulinomas is not necessary. J Am Coll Surg 189 4 (1999) 368-373
45. Lo C.Y., Lam K.Y., Kung A.W., et al. Pancreatic insulinomas: a 15-year experience. Arch Surg 132 8 (1997) 926-930
46. Hiramoto J.S., Feldstein V.A., LaBerge J.M., et al. Intraoperative ultrasound and preoperative localization detects all occult insulinomas. Arch Surg 136 9 (2001) 1020-1025 [discussion: 1025-6]
47. Doherty G.M., Doppman J.L., Shawker T.H., et al. Results of a prospective strategy to diagnose, localize, and resect insulinomas. Surgery 110 6 (1991) 989-996 [discussion: 996-7]
48. Norton J.A., Cornelius M.J., Doppman J.L., et al. Effect of parathyroidectomy in patients with hyperparathyroidism, Zollinger-Ellison syndrome, and multiple endocrine neoplasia type I: a prospective study. Surgery 102 6 (1987) 958-966
49. Fraker D.L., and Norton J.A. The role of surgery in the management of islet cell tumors. Gastroenterol Clin North Am 18 4 (1989) 805-830
50. D'Herbomez M., Pattou F., Nocaudie M., et al. [Usefulness and limits of intraoperative hormone measurements in surgery of endocrine duodeno-pancreatic tumors: experience of 72 cases]. Ann Biol Clin (Paris) 57 2 (1999) 185-190 [French]
51. Machado M.C., Jukemura J., da Cunha J.E., et al. [Surgical treatment of insulinoma: study of 59 cases]. Rev Assoc Med Bras 44 2 (1998) 159-166 [Portuguese]
52. Yedibela S., Reck T., and Hohenberger W. [Resection of liver metastases: goal, timing and results]. Ther Umsch 58 12 (2001) 713-717 [German]
53. Isenberg J.I., Walsh J.H., and Grossman M.I. Zollinger-Ellison syndrome. Gastroenterology 65 1 (1973) 140-165
54. Zollinger R.M., and Ellison E.H. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 142 4 (1955) 709-723 [discussion: 724-8]
55. Modlin I.M., Jaffe B.M., Sank A., et al. The early diagnosis of gastrinoma. Ann Surg 196 5 (1982) 512-517
56. Perry R.R., and Vinik A.I. Clinical review 72: diagnosis and management of functioning islet cell tumors. J Clin Endocrinol Metab 80 8 (1995) 2273-2278
57. Meko J.B., and Norton J.A. Management of patients with Zollinger-Ellison syndrome. Annu Rev Med 46 (1995) 395-411
58. Veldhuis J.D., Norton J.A., Wells Jr. S.A., et al. Surgical versus medical management of multiple endocrine neoplasia (MEN) type I. J Clin Endocrinol Metab 82 2 (1997) 357-364
59. Norton J.A. Gastrinoma: advances in localization and treatment. Surg Oncol Clin N Am 7 4 (1998) 845-861
60. Alexander H.R., Bartlett D.L., Venzon D.J., et al. Analysis of factors associated with long-term (five or more years) cure in patients undergoing operation for Zollinger-Ellison syndrome. Surgery 124 6 (1998) 1160-1166
61. Norton J.A., Doppman J.L., and Jensen R.T. Curative resection in Zollinger-Ellison syndrome: results of a 10-year prospective study. Ann Surg 215 1 (1992) 8-18
62. Wu P.C., Alexander H.R., Bartlett D.L., et al. A prospective analysis of the frequency, location, and curability of ectopic (nonpancreaticoduodenal, nonnodal) gastrinoma. Surgery 122 6 (1997) 1176-1182
63. Weber H.C., Venzon D.J., Lin J.T., et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 108 6 (1995) 1637-1649
64. Jensen R.T. Gastrointestinal endocrine tumours: gastrinoma. Baillieres Clin Gastroenterol 10 4 (1996) 603-643
65. Li M.L., and Norton J.A. Gastrinoma. Curr Treat Options Oncol 2 4 (2001) 337-346
66. Miller T.A. Zollinger-Ellison syndrome: surgery should still play an important role in its management. Gastroenterology 108 5 (1995) 1600-1602
67. Norton J.A., Fraker D.L., Alexander H.R., et al. Surgery increases survival in patients with gastrinoma. Ann Surg 244 3 (2006) 410-419
68. Wank S.A., Doppman J.L., Miller D.L., et al. Prospective study of the ability of computed axial tomography to localize gastrinomas in patients with Zollinger-Ellison syndrome. Gastroenterology 92 4 (1987) 905-912
69. Gibril F., Reynolds J.C., Chen C.C., et al. Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med 40 4 (1999) 539-553
70. Gibril F., Reynolds J.C., Lubensky I.A., et al. Ability of somatostatin receptor scintigraphy to identify patients with gastric carcinoids: a prospective study. J Nucl Med 41 10 (2000) 1646-1656
71. Gomez D., Malik H.Z., Al-Mukthar A., et al. Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: outcome and prognostic predictors. HPB (Oxford) 9 5 (2007) 345-351
72. McEntee G.P., Nagorney D.M., Kvols L.K., et al. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 108 6 (1990) 1091-1096
73. MacFarlane M.P., Fraker D.L., Alexander H.R., et al. Prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia type 1. Surgery 118 6 (1995) 973-979 [discussion: 979-80]
74. Mekhjian H.S., and O'Dorisio T.M. VIPoma syndrome. Semin Oncol 14 3 (1987) 282-291
75. Long R.G., Bryant M.G., Mitchell S.J., et al. Clinicopathological study of pancreatic and ganglioneuroblastoma tumours secreting vasoactive intestinal polypeptide (VIPomas). Br Med J (Clin Res Ed) 282 6278 (1981) 1767-1771
76. Capella C., Polak J.M., Buffa R., et al. Morphologic patterns and diagnostic criteria of VIP-producing endocrine tumors: a histologic, histochemical, ultrastructural, and biochemical study of 32 cases. Cancer 52 10 (1983) 1860-1874
77. Arnold R., Frank M., and Kajdan U. Management of gastroenteropancreatic endocrine tumors: the place of somatostatin analogues. Digestion 55 Suppl 3 (1994) 107-113
78. Nikou G.C., Toubanakis C., Nikolaou P., et al. VIPomas: an update in diagnosis and management in a series of 11 patients. Hepatogastroenterology 52 64 (2005) 1259-1265
79. Schoevaerdts D., Favet L., Zekry D., et al. Vipoma: effective treatment with octreotide in the oldest old. J Am Geriatr Soc 49 4 (2001) 496-497
80. Norton J.A. Neuroendocrine tumors of the pancreas and duodenum. Curr Probl Surg 31 2 (1994) 77-156
81. Boden G. Glucagonomas and insulinomas. Gastroenterol Clin North Am 18 4 (1989) 831-845
82. Maton P.N. Use of octreotide acetate for control of symptoms in patients with islet cell tumors. World J Surg 17 4 (1993) 504-510
83. Krausz Y., Bar-Ziv J., de Jong R.B., et al. Somatostatin-receptor scintigraphy in the management of gastroenteropancreatic tumors. Am J Gastroenterol 93 1 (1998) 66-70
84. Lipp R.W., Schnedl W.J., Stauber R., et al. Scintigraphic long-term follow-up of a patient with metastatic glucagonoma. Am J Gastroenterol 95 7 (2000) 1818-1820
85. Higgins G.A., Recant L., and Fischman A.B. The glucagonoma syndrome: surgically curable diabetes. Am J Surg 137 1 (1979) 142-148
86. Vinik A.I., Strodel W.E., Eckhauser F.E., et al. PPomas, neurotensinomas. Semin Oncol 14 3 (1987) 263-281
87. Konomi K., Chijiiwa K., Katsuta T., et al. Pancreatic somatostatinoma: a case report and review of the literature. J Surg Oncol 43 4 (1990) 259-265
88. Tanaka S., Yamasaki S., Matsushita H., et al. Duodenal somatostatinoma: a case report and review of 31 cases with special reference to the relationship between tumor size and metastasis. Pathol Int 50 2 (2000) 146-152
89. Soga J., and Yakuwa Y. Somatostatinoma/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas. J Exp Clin Cancer Res 18 1 (1999) 13-22
90. Moertel C.G. Karnofsky memorial lecture: an odyssey in the land of small tumors. J Clin Oncol 5 10 (1987) 1502-1522
91. Sarmiento J.M., Heywood G., Rubin J., et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197 1 (2003) 29-37
92. Norton J.A., Kivlen M., Li M., et al. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg 138 8 (2003) 859-866
93. Marlink R.G., Lokich J.J., Robins J.R., et al. Hepatic arterial embolization for metastatic hormone-secreting tumors: technique, effectiveness, and complications. Cancer 65 10 (1990) 2227-2232
94. Perry L.J., Stuart K., Stokes K.R., et al. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery 116 6 (1994) 1111-1116 [discussion: 1116-7]
95. Strosberg J.R., Choi J., Cantor A.B., et al. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control 13 1 (2006) 72-78
96. Cozzi P.J., Englund R., and Morris D.L. Cryotherapy treatment of patients with hepatic metastases from neuroendocrine tumors. Cancer 76 3 (1995) 501-509
97. Mazzaglia P.J., Berber E., Milas M., et al. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 142 1 (2007) 10-19
98. Seifert J.K., Cozzi P.J., and Morris D.L. Cryotherapy for neuroendocrine liver metastases. Semin Surg Oncol 14 2 (1998) 175-183
99. Cosin O., Bilbao J.I., Alvarez S., et al. Right gastric artery embolization prior to treatment with yttrium-90 microspheres. Cardiovasc Intervent Radiol 30 1 (2007) 98-103
100. McStay M.K., Maudgil D., Williams M., et al. Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy. Radiology 237 2 (2005) 718-726
101. Murthy R., Kamat P., Nunez R., et al. Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization. J Vasc Interv Radiol 19 1 (2008) 145-151
102. Delaunoit T., Hobday T., Neczyporenko F., et al. Medical management of pancreatic neuroendocrine tumors. Am J Gastroenterol 103 (2008) 475-483
103. Modlin I.M., Oberg K., Chung D.C., et al. Gastropancreatic neuroendocrine tumours. Lancet Oncol 9 (2008) 61-72
104. Faiss S., Ulrich-Frank P., Wiedenmann B., et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lantreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastropancreatic tumors: the International Lantreotide and Interferon alfa study group. J Clin Oncol 21 14 (2003) 2689-2696
105. Sun W., Lipsitz S., Haller D., et al. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: ECOG Study E1281. J Clin Oncol 23 22 (2005) 4897-4904
106. Moertel C.G., and Hanley J.A. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 2 (1979) 327-334
107. Moertel C., Lefkopoulo M., Lipsitz S., et al. Streptozocin-doxorubicin, stretpozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326 (1992) 519-523
108. Kouvaraki M., Ajani J., Yao J., et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22 (2004) 4762-4771
109. Ramanathan R.K., Cnaan A., Haller D.G., et al. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma: study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 12 (2001) 1139-1143
110. Bukowski R., Johnson K., Costanzi J., et al. A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. Cancer 60 (1987) 2891-2895
111. Kulke M.H., Stuart K., Enzinger P.C., et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24 (2006) 401-406
112. Nakakura E.K., and Bergsland E.K. Islet cell carcinoma: neuroendocrine tumors of the pancreas and periampullary region. Hematol Oncol Clin North Am 21 (2007) 457-473
113. Duran I., Salazar R., Casanovas O., et al. New drug development in digestive neuroendocrine tumors. Ann Oncol 18 (2007) 1307-1313
114. Kulke M., Lenz H.J., Meropol N.J., et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26 20 (2008) 3403-3410
115. Hobday D.J., Rubin J., Holen K., et al. MC044h, a phase 2 trial of sorafenib in patients with metastatic neuroendocrine tumors: a phase 2 consortium study. ASCO Annual Meeting Proceedings, June 2007; Chicago, IL. J Clin Oncol vol 25 No 18S (2007) [abstract 4504]
116. Duran I., Le L., Saltman D., et al. A phase II trial of temsirolimus in metastatic neuroendocrine tumors. ASCO Annual Meeting Proceedings, June 2007; Chicago, IL. J Clin Oncol vol 23 No 16S (2005) [abstract 3096]
117. Yao J.C., Phan A.T., Chang D.Z., et al. Phase II study of RAD001 (everolimus) and depot octreotide (Sandostatin LAR) in patients with advanced low grade neuroendocrine carcinoma. ASCO Annual Meeting Proceedings, June 2007; Chicago, IL. J Clin Oncol vol. 24 (2006) [abstract 4042]